AHCL/ SE/ 17 /2018-19 May 24, 2018

7FBm49gldb9Rgd:Om:F9bEBm dD/bAl9m 1lSlgBAm (:yaf RmecLiR R()9,., 8inah B MRmbpR,spiR9nloicy, MRmbpR):) HtlSRg 3-- -4/ DLCI7Dl:-65A-0-12	,6-m 1lSlgBAm :coRprlcmr nd9npon pRrlccpugacg / (()Alnnp, L-E-Onvcpq,:RiRl Lrpccr) HtlSRg 3-- --/
6lS :dR,m, 3587,40,4m	6:f lem-dAB,m))((()m

Lpl gs 3clol ,

Sub: Outcome of the Board Meeting – Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)

Ref : Letter no. AHCL/ SE/ 14 /2018-19 dated May 16, 2018

e l rplm p pq yl s p) s r s p rl rpl l o pLs pn p rp
L l l s pp s q rp (May 24, 2018) rlo s p –lytlE

l/ Approved the Audited Financial Results p rpf l p o lpl p opcl nr :6, :56D
l pn p mopo rpl osn s l tpp pp t rpyo ol)cl :A, :57D)/ hrp l p
ly q t r rpa op p opl ot qp (s mpoc3 /l q q L(/bbe, q l
H os t p ny poF

m/ Recommended Final Dividend pRs. 0.85 4 pp s rl p 2, 92, 30,630 p t rl p
pp/ 63.plnr p y lto p rpps l nslpl :57C. :56D/

hrp pt lyos sop sp, l po rpH Rp p lypp u q,symp lto rpp tqtm p
rl pr ops rs5 ol pl Rp p dpp s q0

hrp l l ccpp t rq p nlpc66055H0c0)8gi) l on ny lopS (()()e/c1):gi)

ip p p lvp rplm p pn l o pm tl npoplm p ppp po
pq yl s pMla bdLg

hrl vs q ,

l plt rp yy ,

For Amrutanjan Health Care Limited

(M Srinivasan)
Company Secretary & Compliance Officer

AMRUTANJAN HEALTH CARE LIMITED CHENNAI 600 004

Encl:

6/ H ot pOt l nsdp yp rpf l p olpl p opcl nr :6- :56D
:0 a op p op H os p rpf lgpp l olpl p opcl nr :7, :56D
:/ Lpn l l s opppq/ ::):))o) pMla bdLg
B2Ssqr sqr

,agii(:cM:cm .C:RhHm-:gCm2LaLhCAm

g5:) (n l / B: ,BD(, i c v p t ,
l t c , t E55 55B
gt lt , g t/
g ML6-BB 0 :BLL BBED
)L7–BB – :BEE L555
ft O)L7–BB- :BLL BDID

e– t Ry t bt t t 1
s u p S 2 t t 1
g f l 3a h l55 . B:D BDBD
dhm4 i :C :A9rm8LAFoid55559H

AMRUTANJAN HEALTH CARE LIMITED

CIN No : L24231TN1936PLC000017

Regd Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

10. During the current quarter, the Company has decided to discontinue the operations of its Chemical division. Accordingly, the results for the comparative periods in this Statement have been revised to exclude the operations of the Chemical division. The results of the discontinued operations are presented below.

	Particulars	Quarter ended			Year ended	
		March 31, 2018 (Audited - refer note 3)	December 31, 2017 (Unaudited)	March 31, 2017 (Audited - refer note 3)	March 31, 2018 (Audited)	March 31, 2017 (Audited)
I	Total revenue	131.61	11.00	225.09	228.07	478.06
II	Total expenses	59.50	32.65	266.18	244.25	624.25
III	**Profit/ (loss) before tax (I - II)**	**72.11**	**(21.65)**	**(41.09)**	**(16.18)**	**(146.19)**
IV	Tax benefit	0.72	2.64	15.11	8.56	15.11
V	**Profit/ (loss) from discontinuing operations (III + IV)**	**72.83**	**(19.01)**	**(25.98)**	**(7.62)**	**(131.08)**

11. Previous period figures have been reclassified wherever required to conform to the classification of the current period.

For Amrutanjan Health Care Limited

S Sambhu Prasad
Chairman & Managing Director

Date: May 24, 2018
Place: Chennai

BSR & Co. LLP ★ Chartered Accountants ★